ArticleMethods in molecular biology (Clifton, N.J.)2025
Design and Preliminary Screen of Antisense Oligonucleotides.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antisense Oligonucleotides (ASOs) are short, synthetic oligonucleotides that specifically bind to target RNA sequences to modulate their expression. ASOs have applications in both research and clinical therapy, with more than eight FDA-approved products and numerous others in clinical development. The functionality of ASOs is determined by their nucleotide sequence and the chemical modifications they carry. These modifications can define the ASO's function, and increase its stability, safety, and distribution in the body. In this chapter, we offer a comprehensive guide to designing RNAse-H1 recruiting ASOs, including guideline for sequence selection and chemical modifications. Additionally, we will outline a protocol for initial screenings of ASO libraries, providing recommendations for selection of the suitable screening platform.
Indexed as
Identifiers
40163297What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.